Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection

Vaccine

Volumn 29, Issue 24, 2011, Pages 4132-4141

  Holzer, Georg W ^a   Coulibaly, Sogue ^a   Aichinger, Gerald ^a   Savidis Dacho, Helga ^a   Mayrhofer, Josef ^a   Brunner, Susanne ^a   Schmid, Karl ^a   Kistner, Otfried ^a   Aaskov, John G ^b   Falkner, Falko G ^a   Ehrlich, Hartmut ^a   Barrett, P Noel ^a   Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Antibody dependent enhancement; IFN R knock out mice; Immunization; Passive; Ross River virus; Vaccines

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; FORMALDEHYDE; VIRUS VACCINE;

ADULT; ANIMAL CELL; ANTIBODY TITER; ARTICLE; AUSTRALIA; CELL CULTURE; CHIKUNGUNYA ALPHAVIRUS; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURAL ANTHROPOLOGY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MOUSE; NONHUMAN; POLYARTHRITIS; PRIORITY JOURNAL; ROSS RIVER ALPHA VIRUS; STATISTICAL SIGNIFICANCE; ULTRAVIOLET RADIATION; VIREMIA; VIROGENESIS;

ADOLESCENT; ADULT; ALPHAVIRUS INFECTIONS; ANIMALS; BIOLOGICAL MARKERS; CHIKUNGUNYA VIRUS; CROSS PROTECTION; FEMALE; HUMANS; IMMUNIZATION; MALE; MICE; ROSS RIVER VIRUS; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VIRAL VACCINES; VIREMIA; YOUNG ADULT;

EID: 79956117031     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.089     Document Type: Article

References (43)

1. Fraser J.R. Epidemic polyarthritis and Ross River virus disease. Clin Rheum Dis 1986, 12(2):369-388.
2. Harley D., Sleigh A., Ritchie S. Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev 2001, 14(4):909-932.
3. Suhrbier A., La L.M. Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 2004, 16(4):374-379.
4. Aaskov J.G., Chen J.Y., Hanh N.T., Dennington P.M. Surveillance for Ross River virus infection using blood donors. Am J Trop Med Hyg 1998, 58(6):726-730.
5. Strauss J.H., Strauss E.G. The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 1994, 58(3):491-562.
6. Aaskov J., Williams L., Yu S. A candidate Ross River virus vaccine: preclinical evaluation. Vaccine 1997, 15(12-13):1396-1404.
7. Kistner O., Barrett N., Bruhmann A., et al. The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans. Vaccine 2007, 25(25):4845-4852.
8. Yu S., Aaskov J.G. Development of a candidate vaccine against Ross River virus infection. Vaccine 1994, 12(12):1118-1124.
9. Food and Drug Administration. FDA Guidance for Industry: Animal models - Essential elements to address under the Animal Rule. Available from: [accessed 13.01.09. Ref Type: Internet Communication]. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078923.pdf.
10. Lidbury B.A., Simeonovic C., Maxwell G.E., Marshall I.D., Hapel A.J. Macrophage-induced muscle pathology results in morbidity and mortality for Ross River virus-infected mice. J Infect Dis 2000, 181(1):27-34.
11. Morrison T.E., Whitmore A.C., Shabman R.S., Lidbury B.A., Mahalingam S., Heise M.T. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol 2006, 80(2):737-749.
12. Grieder F.B., Vogel S.N. Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. Virology 1999, 257(1):106-118.
13. Couderc T., Chretien F., Schilte C., et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 2008, 4(2):e29.
14. Ryman K.D., Klimstra W.B., Nguyen K.B., Biron C.A., Johnston R.E. Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J Virol 2000, 74(7):3366-3378.
15. Huang S., Hendriks W., Althage A., et al. Immune response in mice that lack the interferon-gamma receptor. Science 1993, 259(5102):1742-1745.
16. Muller U., Steinhoff U., Reis L.F., et al. Functional role of type I and type II interferons in antiviral defense. Science 1994, 264(5167):1918-1921.
17. Halstead S.B., O'Rourke E.J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 1977, 146(1):201-217.
18. Halstead S.B., O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977, 265(5596):739-741.
19. Huisman W., Martina B.E., Rimmelzwaan G.F., Gruters R.A., Osterhaus A.D. Vaccine-induced enhancement of viral infections. Vaccine 2008, 27:505-512.
20. Takada A., Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003, 13(6):387-398.
21. Rulli N.E., Suhrbier A., Hueston L., et al. Ross River virus: molecular and cellular aspects of disease pathogenesis. Pharmacol Ther 2005, 107(3):329-342.
22. Linn M.L., Aaskov J.G., Suhrbier A. Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. J Gen Virol 1996, 77(Pt 3):407-411.
23. Mims C.A., Murphy F.A., Taylor W.P., Marshall I.D. Pathogenesis of Ross River virus infection in mice. I. Ependymal infection, cortical thinning, and hydrocephalus. J Infect Dis 1973, 127(2):121-128.
24. Murphy F.A., Taylor W.P., Mims C.A., Marshall I.D. Pathogenesis of Ross River virus infection in mice. II. Muscle, heart, and brown fat lesions. J Infect Dis 1973, 127(2):129-138.
25. Faragher S.G., Meek A.D., Rice C.M., Dalgarno L. Genome sequences of a mouse-avirulent and a mouse-virulent strain of Ross River virus. Virology 1988, 163(2):509-526.
26. Grillberger L., Kreil T.R., Nasr S., Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 2009, 4(2):186-201.
27. Reed J.L., Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27(3):493-497.
28. Tsetsarkin K.A., Vanlandingham D.L., McGee C.E., Higgs S. A single mutation in Chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007, 3(12):e201.
29. Riches A.C., Sharp J.G., Thomas D.B., Smith S.V. Blood volume determination in the mouse. J Physiol 1973, 228(2):279-284.
30. Griffin D.E. Alphaviruses. Fields virology 2007, 1023-1067. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
31. Mrkic B., Pavlovic J., Rulicke T., et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol 1998, 72(9):7420-7427.
32. Fiette L., Aubert C., Muller U., et al. Theiler's virus infection of 129 Sv mice that lack the interferon alpha/beta or interferon gamma receptors. J Exp Med 1995, 181(6):2069-2076.
33. Garcia-Sastre A., Durbin R.K., Zheng H., et al. The role of interferon in influenza virus tissue tropism. J Virol 1998, 72(11):8550-8558.
34. Price G.E., Gaszewska-Mastarlarz A., Moskophidis D. The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. J Virol 2000, 74(9):3996-4003.
35. Kaltenbock A., Dubischar-Kastner K., Eder G., et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study. Vaccine 2009, 27(33):4483-4489.
36. Loew-Baselli A., Konior R., Pavlova B.G., et al. Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies. Vaccine 2006, 24(24):5256-5263.
37. Van Damme P., Leroux-Roels G., Law B., et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 2001, 65(1):6-13.
38. Curran M., Harvey B., Crerar S., et al. Australia's notifiable diseases status, 1996, Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 1997, 21(20):281-307.
39. Aaskov J.G., Ross P., Davies C.E., et al. Epidemic polyarthritis in northeastern Australia, 1978-1979. Med J Aust 1981, 2(1):17-19.
40. Morier L., Kouri G., Guzman G., Soler M. Antibody-dependent enhancement of dengue 2 virus in people of white descent in Cuba. Lancet 1987, 1(8540):1028-1029.
41. Wallace M.J., Smith D.W., Broom A.K., et al. Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 2003, 84(Pt 7):1723-1728.
42. Kreil T.R., Eibl M.M. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol 1997, 71(4):2921-2927.
43. Lobigs M., Larena M., Alsharifi M., Lee E., Pavy M. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective value against Murray Valley encephalitis virus. J Virol 2008, 83(6):2436-2445.